We use both our own and third-party cookies for statistical purposes and to improve our services. If you continue to browse, we consider that you accept the use of these.

Move beyond single-analyte to multidimensional.

Achieving true precision medicine requires a shift to multidimensional models.

WE BUILD RNA PREDICTIVE DIAGNOSTICS

1. WELL-DESIGNED
CLINICAL TRIALS

We recruit well-annotated patient cohorts in our clinical studies, like the multicenter PREDAPT trial.

2. IMMUNE
PROFILING

Cofactor’s ImmunoPrism platform uncovers each patient’s immune profile using RNA from FFPE solid tumor specimens.

3. MULTIDIMENSIONAL BIOMARKER

Using our machine learning-based Predictive Immune Modeling approach, we bring together the most important immune signals into a predictive biomarker.

4. LAUNCH ONCOPRISM CLINICAL TEST

These biomarkers are used in our OncoPrism tests which help clinicians predict the likelihood a patient will respond to immunotherapy.

FOCUSED ON IMMUNO-ONCOLOGY APPLICATIONS

Using our ImmunoPrism platform in well-designed retrospective clinical studies, we discover multidimensional RNA biomarkers and build diagnostic tests under the OncoPrism name.

Cofactor’s technology is protected by United States Patent #20200227138.  We have the freedom to operate in all cancer types and predicting response to all immunotherapies.

Animation of steps for individual immune profile process

USE IMMUNOPRISM TO IMMUNE PROFILE PATIENTS

RNA is extracted from FFPE tissue collected from a cancer patient’s tumor. This RNA is analyzed using ImmunoPrism ® and compared to our database of immune HEMs to quantify key immune signals including both cells and transcripts.

BUILD POWERFUL BIOMARKERS

We build multidimensional biomarkers by using the immune profiling data from a well-defined patient cohort. The ImmunoPrism data is used in our machine learning software to identify the combination of analytes that will result in the highest predictive value. The performance of the biomarker is evaluated, and then validated.

Animation of steps for diagnostic and drug development

DEPLOY ONCOPRISM DIAGNOSTIC FOR PATIENT TREATMENT DECISION

Our predictive diagnostics, built using these multidimensional biomarkers, are deployed in our CAP/CLIA laboratory as a laboratory developed test (LDT). Prospectively, individual patient’s immune profiles are analyzed and compared to the multidimensional biomarker to generate a Response Score which predicts likelihood of response to therapy. These results may be used in clinical decision making.

Cofactor offers products both for Research Use Only (not to be used as a diagnostic assay) and within our CAP-certified laboratory.  Please contact us to discuss which option is right for your application.

Start typing and press Enter to search